Surgical Management of Recurrent Endometrial Cancer

2004 ◽  
pp. 327-341
Author(s):  
Nicholas Lambrou ◽  
Luis Mendez ◽  
Manuel Penalver
Keyword(s):  
Endometrial Cancer ◽  
Surgical Management ◽  
Recurrent Endometrial Cancer

scholarly journals IMPACT OF HORMONAL BIOMARKERS ON RESPONSE TO HORMONAL THERAPY IN ADVANCED AND RECURRENT ENDOMETRIAL CANCER:

2021 ◽  
Author(s):  
Willem Jan VAN WEELDEN ◽  
Roy I. LALISANG ◽  
Johan BULTEN ◽  
Kristina LINDEMANN ◽  
Heleen J. VAN BEEKHUIZEN ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hormonal Therapy ◽  
Recurrent Endometrial Cancer

scholarly journals 429 Identification of clinicopathological prognostic factors in recurrent endometrial cancer

2020 ◽  
Author(s):  
Y Koike ◽  
M Takenaka ◽  
J Suzuki ◽  
Y Shoburu ◽  
K Tomita ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Recurrent Endometrial Cancer

Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel

2000 ◽  
Vol 160 (1) ◽  
pp. 9-12 ◽  
Author(s):  
Shunichiro Ota ◽  
Toru Sugiyama ◽  
Kimio Ushijima ◽  
Kan Komai ◽  
Keizo Fujiyoshi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Successful Treatment ◽  
Weekly Paclitaxel ◽  
Recurrent Endometrial Cancer

Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study

2021 ◽  
Vol 161 (1) ◽  
pp. 104-112
Author(s):  
Robert L. Coleman ◽  
Wei Hu ◽  
Pamela Soliman ◽  
Alpa Nick ◽  
Pedro T. Ramirez ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Advanced Stage ◽  
Translational Study ◽  
Recurrent Endometrial Cancer

Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

2021 ◽  
Author(s):  
David A. Barrington ◽  
Paulina J. Haight ◽  
Cody Calhoun ◽  
Crystal Tubbs ◽  
David E. Cohn ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Recurrent Endometrial Cancer

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

2017 ◽  
Vol 27 (2) ◽  
pp. 258-266 ◽  
Author(s):  
Patricia Pautier ◽  
Ignace Vergote ◽  
Florence Joly ◽  
Bohuslav Melichar ◽  
Elzbieta Kutarska ◽  
...  
Keyword(s):  
Overall Survival ◽  
Endometrial Cancer ◽  
Adverse Events ◽  
Confidence Interval ◽  
Progression Free Survival ◽  
Megestrol Acetate ◽  
Phase 2 ◽  
Open Label ◽  
Free Survival ◽  
Recurrent Endometrial Cancer

ObjectiveAdvanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial cancer.MethodsThis was a phase 2, multicenter, international, open-label, randomized (1:1), 2-arm study of the STS inhibitor oral irosustat 40 mg/d versus oral megestrol acetate 160 mg/d in women with advanced/metastatic or recurrent estrogen receptor–positive endometrial cancer. The primary end point was the proportion of patients without progression or death 6 months after start of treatment. Secondary end points included progression-free survival, time to progression, overall survival, and safety.ResultsSeventy-one patients were treated (36 with irosustat, 35 with megestrol acetate). The study was prematurely stopped after futility analysis. Overall, 36.1% and 54.1% of patients receiving irosustat or megestrol acetate had not progressed or died at 6 months, respectively. There were no statistically significant differences between irosustat and megestrol acetate in response and overall survival rates. Irosustat patients had a median progression-free survival of 16 weeks (90% confidence interval, 9.0–31.4) versus 40 weeks (90% confidence interval, 16.3–64.0) in megestrol acetate patients. Treatment-related adverse events occurred in 20 (55.6%) and 13 (37.1%) patients receiving irosustat or megestrol, respectively. Most adverse events in both groups were grade 1 or 2.ConclusionsAlthough irosustat monotherapy did not attain a level of activity sufficient for further development in patients with advanced/recurrent endometrial cancer, this study confirms the activity of hormonal treatment (megestrol acetate) for this indication.

Sign in / Sign up

Export Citation Format

Share Document